# Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

> **NCT00753207** · PHASE1 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** epirubicin hydrochloride
- **DRUG:** lapatinib ditosylate
- **OTHER:** biomarker analysis
- **OTHER:** immunohistochemistry staining method
- **OTHER:** liquid chromatography
- **OTHER:** mass spectrometry

## Key facts

- **NCT ID:** NCT00753207
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-11
- **Final completion:** 2012-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753207, "Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00753207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*